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Background: IL-31 is a novel cytokine that has been implicated in allergic diseases such as atopic dermatitis
and more recently asthma. While IL-31 has been well studied in skin conditions such as atopic dermatitis,
little is known about the role IL-31 plays in asthma and speciﬁcally the differentiation process of the
bronchial epithelium, which is central to the pathogenesis of allergic asthma.
Methods: We examined the effects of IL-13 (20 ng/ml), IL-31 (20 ng/ml) and an IL-13/IL-31 combination
stimulation (20 ng/ml each) on the in vitromucociliary differentiation of paediatric bronchial epithelial cells
(PBECs) from healthy patients (n¼6). IL-31 receptor (IL-31-RA) expression, markers of differentiation (goblet
and ciliated cells), transepithelial electrical resistance (TEER), quantiﬁcation of goblet and ciliated cells, real
time PCR for MUC5AC, ELISA for VEGF, EGF and MCP-1 (CCL-2) and ELISA for MUC5AC were assessed.
Results: We found that well-differentiated PBECs expressed IL-31-RA however it’s expression did not
increase upon stimulation with IL-31 or either of the other treatments. TEER indicated good formation of
tight junctions which was found to be similar across all treatment groups (p¼0.9). We found that IL-13
alone signiﬁcantly reduced the number of ciliated cells compared with unstimulated (IL-13 stimuation:
mean¼4.8% (SD¼2.5); unstimulated: mean¼15.9%, (SD¼7.4), po0.01). IL-31 stimulation alone had no
effect on ciliated cells whereas the IL-13/IL-31 combination stimulation signiﬁcantly reduced the number of
ciliated cells compared with control (IL-13/IL-31 combination: mean¼5.1% (SD¼4.6); unstimulated:
mean¼15.9%, (SD¼7.4), po0.01). We did not ﬁnd that the combination of IL-13 and IL-31 had any
additional effects to that of IL-13 alone. MUC5AC mRNA and secreted mucin was found in similar levels
between unstimulated and all treatments, however IL-13 increased levels of MUC5AC mRNA by a factor of
2.84, albeit not signiﬁcantly, compared with unstimulated cultures (IL-13 stimulation: mean¼2.84
(SD¼3.79); unstimulated: mean¼1.0).
Conclusions: IL-31RA receptor is present on well-differentiated paediatric bronchial epithelial cells. IL-31
does not exhibit any detrimental effects on mucociliary differentiation. IL-31 does not appear to have a
synergistic effect when combined in culture with IL-13, in the differentiation process.
& 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Allergic asthma typically begins during childhood and progresses
into adulthood with characteristic pathological changes occurring
in the bronchial epithelium [1–3]. The main pathological change inediatric Bronchial Epithelial
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Y-NC-ND license.asthma is known as airways remodelling, a difﬁcult to reverse
process which is associated with goblet cell hyperplasia of the
bronchial epithelium and subsequent mucus hyper-secretion, which
in turn causes airﬂow obstruction. Such characteristic changes are
associated with increased Th2 cytokine production from T lympho-
cyte inﬁltration, including IL-4, IL-5, IL-9, IL-13 and more recently
IL-31 [4–6].
Goblet cells are the main mucus-producing cell type within the
airway epithelium and goblet cell hyperplasia is a common pathol-
ogy of asthma [7]. IL-13 has been implicated as a key pathogenic
cytokine in allergic asthma and Kondo and colleagues have sug-
gested that it contributes to the differentiation of ciliated cells into
goblet cells in asthmatic epithelium [8,9]. In addition it has been
previously reported that both paediatric and adult epithelium
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of MUC5AC, the major mucus forming mucin, in both healthy and
asthmatic epithelium [10–14]. IL-13 has been studied in detail using
a number of different models in an attempt to re-create the
asthmatic phenotype. Early studies included experiments using
mice sensitised with ovalbumin, which then receive a further
allergic ‘hit’ resulting in an increase in MUC5AC expression and
goblet cell number [15,16]. The effects of IL-13 have also been
assessed using in vitro adult normal human bronchial epithelial cell
cultures and it has been shown to increase goblet cell density by ten
times as well as increasing MUC5AC expression, indicating a central
role for IL-13 in allergic asthma [17].
IL-31 is produced by activated CD4þ T cells, mainly from the
Th2 subset [6] and may work synergistically with IL-13 to
modulate bronchial epithelial cell function. IL-31 over-expression
has been well documented as having pathogenic effects in atopic
dermatitis (AD) including skin inﬂammation, pruritis and severe
dermatitis [6,18] and IL-31 levels in serum or at mRNA level may
be a valuable indicator of allergic asthma [19]. IL-31 is known to
act through a hetero-dimeric receptor composed of IL-31 receptor
A (IL-31RA) and oncostatin M receptor (OSMR), which has been
shown to activate signal transducer and activator of transcription
factor 3 (STAT-3) in alveolar epithelial cells transfected with
IL-31-RA, a pathway shared by IL-9 which has also been impli-
cated in goblet cell hyperplasia and airways remodelling [20–22].
IL-31 activates STAT-1 and STAT-5 to a lesser extent [23,24], a
similarity shared with IL-9. IL-31 has been shown to signiﬁcantly
increase epidermal growth factor (EGF) in a transformed human
bronchial epithelial cell line which is linked with up-regulation of
mucin transcription [25,26]. Human bronchial epithelial cells
have been shown to express IL-31-RA and are thought to be
direct targets for IL-31 [20]. It is important therefore to study IL-
31 further, in a human paediatric epithelial cell model [27] to
identify its effect on paediatric airways.
To further explore the role of IL-31 in mucociliary differentia-
tion in comparison with IL-13, a known pathogenic cytokine in
asthma, we have used a 3-D paediatric well-differentiated pri-
mary bronchial epithelial cell model [14,27] with which to study
the effects of IL-31 individually and combined with IL-13.
1.1. Hypothesis
We hypothesised that bronchial epithelial cells from healthy
children when exposed to IL-31 or an IL-13/IL-31 combination
stimulation would alter their mucociliary phenotype towards that
of an asthmatic epithelium.2. Materials and methods
2.1. Subjects
Children less than 12 years of age (mean age 7 years [range: 2–12
years]) attending elective surgical procedures at the Royal Belfast
Hospital for Sick Children were recruited. A doctor administered
semi-structured pro-forma was used to ensure that the children were
otherwise healthy and had no respiratory symptoms. Written
informed parental consent was obtained. This study was approved
by the Ofﬁce of the Research Ethics Committees of Northern Ireland
(ORECNI).
2.2. Sampling
Non-bronchoscopic bronchial brushings were obtained from
healthy children (n¼6) as previously described [27,28]. PBECs
were then cultured as previously described [14,27]. All brushwashings were analysed for viruses using a multi-viral PCR
analysis and only uncontaminated cultures were used [29].
2.3. ALI cultures for establishment of WD-PBECs
ALI cultures were grown as previously described [14,27,30,31].
All cells from subjects used in this study were grown at ALI at
passage 2 in ALI medium consisting of a 50:50 mixture of AEGM
(Promocell, Heidelberg, Germany) and DMEM (Invitrogen Ltd,
Paisley, UK) supplemented with bovine pituitary extract (52 mg/
ml), epidermal growth factor (0.5 ng/ml), insulin (5 mg/ml),
hydrocortisone (0.5 mg/ml), epinephrine (0.5 mg/ml), transferrin
(10 mg/ml), bovine serum albumin (1.5 mg/ml), penicillin/strepto-
mycin (100 IU/ml/100 mg/ml) and retinoic acid (50 nM). The cells
were grown in transwells submerged for the ﬁrst 9 to 14 days,
during which time the culture medium was changed on day 1 and
every other day thereafter. Once the cells reached 100% con-
ﬂuence, ALI was created by removing the apical medium and
restricting the culture feeding to the basolateral compartment.
Following ALI creation, the culture medium was changed on
alternate days and the cells were then differentiated over 21
day to ensure full differentiation as assessed by the presence of
beating cilia and mucus on the apical surface of the cultures.
2.4. Stimulation of WD-PBECs with IL-13, IL-31 and an IL-13/IL-31
combination
Following establishment of ALI, cells were fed basolaterally
every other day for 21 day with ALI medium supplemented with
recombinant human IL-13 (20 ng/ml), IL-31 (20 ng/ml) or an
IL-13/IL-31 combination (20 ng/ml each) (PeptroTech EC Ltd,
Scotland, UK) at concentrations in line with our previous study
using IL-13 [14] as well as with other studies which have ranged
from 0.1 ng/ml to 100 ng/ml, in order to demonstrate any poten-
tial dose response [8,17,32–35]. The apical side was washed
weekly with PBS and aliquots were stored for further analysis.
2.5. Immunoﬂuorescence (IF) and confocal microscopy
Cultures were ﬁxed in 10% formalin and washed three times in
PBS. Cells were permeabilised using 0.5% Triton-X100 (Sigma-
Aldrich, Dorset, UK) for 1 h at room temperature followed by three
washes in PBS. Cells were then exposed to either a 1:200 dilution of
rabbit anti-MUC5AC primary antibody (goblet cells) (Santa Cruz, CA,
USA), a 1:700 dilution of mouse anti-acetylated alpha tubulin
primary antibody (ciliated cells) (Abcam, Cambridge, UK) or a
1:100 dilution of goat polyclonal anti-IL-31-RA-Fluorescein antibody
(R&D Systems, Abingdon, UK) overnight at 4 1C. Negative controls
were subjected to routine conditions with the omission of the
primary antibody. After washing, cells were exposed to either a
1:250 dilution of Alexaﬂuor 568 goat-anti mouse IgG (ciliated cells)
(Invitrogen Ltd, Paisley, UK) or a 1:100 dilution of FITC 488 goat
anti-rabbit IgG (goblet cells) (Abcam, Cambridge, UK) for 1 h at 4 1C
in the dark. Cells were once again washed three times in PBS and the
membrane was then cut out using a scalpel and mounted on a
microscope slide using Vectashield with DAPI (Vector Laboratories,
Peterborough, UK). Fluorescent images were viewed on a Leica SP5
confocal DMI 6000 inverted microscope equipped with a krypton-
argon laser as the source for the ion beam using a x40 oil immersion
objective (numerical aperture 1.25). Images were captured and
viewed using LAS AF (Leica) acquisition software.
2.6. Transepithelial electrical resistance (TEER)
TEER was measured on days 7, 14 and 21 to ensure the
formation and integrity of tight junctions between cells in the
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FL, USA) [36].
2.7. Immunocytochemistry (ICC) for goblet and ciliated cell markers
Cultures were washed with PBS and trypsinised with cytospin
slides being subsequently made by spinning 5104 cells/slide.
Goblet cells and ciliated cells were detected using a 1:200
dilution of mouse monoclonal antibody against MUC5AC (Abcam,
Cambridge, UK) and a 1:700 dilution of mouse monoclonal anti-
body against acetylated alpha tubulin (Abcam, Cambridge, UK),
respectively, for 2 h at room temperature. Negative controls were
subjected to routine conditions with the omission of the primary
antibody. Speciﬁc binding was detected by a micro-polymer of
active peroxidase coupled to anti-mouse IgG secondary antibo-
dies (ImmPressTM Universal Reagent, Vector Laboratories, Peter-
borough, UK). These slides were stained using DAB peroxidase
substrate kit (Vector Laboratories, Peterborough, UK) and coun-
terstained with haematoxylin (Sigma-Aldrich, Dorset, UK). Slides
(n¼4 per patient per treatment) were mounted using DPX (D&H,
Belfast, UK) and viewed under a light microscope. The numbers of
positive cells for each stain are represented as a mean % of the
total number of cells counted per slide. 1000 cells per slide were
counted.
2.8. RNA extraction, cDNA synthesis and quantitative real-time PCR
for MUC5AC mRNA
WD-PBECs harvested for RNA extraction were detached by
trypsinisation from the membrane and stored in RNAlater
(Applied Biosystems, Warrington, UK) to stabilise the cellular
RNA proﬁle. Total RNA was extracted from stabilized cells using
an RNeasy Mini kit (Qiagen, Crawley, UK) according to the
manufacturer’s instructions and quantiﬁed on a spectrophot-
ometer. The transcription of total mRNA to cDNA was performed
using First Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche,
UK) according to the manufacturer’s protocol. For the real time
PCR reaction, the DNA ampliﬁcation was carried out using the
Fast Start Universal SYBR Green Master (Rox) (Roche, UK) accord-
ing to the manufacturers’ protocol. For each PCR reaction separate
PCR Master Mixes were prepared containing either GAPDH
(housekeeping gene) (Tebu-bio, Peterborough, UK) or MUC5AC
primers. MUC5AC primers were designed according to the follow-
ing description (Invitrogen, Paisley, UK):
Forward 50 TCC TTT CGT GTT GTC ACC GA 30 localisation on
cDNA: 2874 bp
Reverse 50 TCT TGA TGG CCT TGG AGC 30 localisation on cDNA:
2943 bp
A ﬁnal total volume of 10 ml was constituted with the addition
of 1 ml of cDNA added into each Master Mix. Samples were placed
into individual wells in triplicate in a Thermo-Fast 96-well
detection plate and run on the spectroﬂuorometric thermal cycler
AB 7000 (AB Prism).
2.9. ELISA measuring MUC5AC mucin
Production of MUC5AC mucin in the apical washes from WD-
PBECs was measured using an in-house MUC5AC ELISA adapted
from Takeyama et al. [25]. Since no MUC5AC standard was
commercially available, this ELISA produced a semi-quantitative
analysis of the production of MUC5AC mucin by comparing
stimulated cultures to unstimulated cultures. A 96-well high-
binding ELISA plate (Corning Costar, USA) was coated with
experimental samples at 37 1C overnight. The plate was then
washed three times with PBS. Wells were blocked with a solution
of 2% BSA in PBS for 1 h at room temperature. Following threewashes with PBS, samples were exposed to a primary mouse anti-
MUC5AC monoclonal antibody (Abcam, Cambridge, UK) diluted
1:200 in PBS containing 0.05% Tweens20 (Sigma-Aldrich, Dorset,
UK). After incubating for 1 h, the plate was washed three times and
labelled with an HRP-conjugated goat anti-mouse IgG (Jackson
Laboratories, USA) diluted to 1:10,000 in PBSþ0.05% Tweens20
and incubated for 1 h. After the secondary antibody incubation, the
plate was washed with PBS, and the colour reaction was developed
with 100 ml of TMB (Millipore, UK) per well incubated for 15 min
at room temperature in the dark. A 1 M H2SO4 solution was then
added to halt colour development and optical density was read at
450 nm with background correction of 570 nm.
2.10. ELISA measuring VEGF, EGF and MCP-1 (CCL-2)
Production of VEGF, EGF and MCP-1 by WD-PBECs was
assessed using commercial ELISAs (PeProTech EC, Scotland, UK)
following manufacturers’ instructions. Initial experiments
informed of the need to dilute samples (1:3) in order to measure
VEGF and EGF within the limits of detection for the assay. MCP-1
ELISA used neat samples. Results show concentrations corrected
for dilution factor measured in pg/ml.
2.11. Statistical analysis
Data was expressed as mean (SD). One way ANOVA (with
Bonferroni correction) and Students t test were used to make
between group comparisons. A p value of o0.05 was taken as
indicating statistical signiﬁcance.3. Results
3.1. IL-31-RA is present on primary bronchial epithelial cells but is
not altered following treatment with IL-13, IL-31 or an IL-13/IL-31
combination
Visually we found that IL-31-RA was expressed in WD-PBECs
across all treatment groups (Fig. 1A–H) with there being no obvious
differences between any of the treatments or unstimulated cultures.
Negative controls showed no evidence of non-speciﬁc binding
(Fig. 1I and J).
3.2. TEER measurements are not altered when PBECs are stimulated
with IL-13, IL-31 or an IL-13/IL-31 combination
In all cultures we observed good tight junction formation from
day 7 through to day 21. TEER values at D21 after stimulation with
IL-13, IL-31 and an IL-13/IL-31 combination were similar to unsti-
mulated values (p¼0.9) (Fig. 2).
3.3. IL-13 but not IL-31 decreases expression of ciliated cells whereas
goblet cells remain unchanged
We found IL-13 stimulation signiﬁcantly reduced the number of
ciliated cells compared with unstimulated (IL-13 stimuation: mean¼
4.8% (SD¼2.5); unstimulated: mean¼15.9%, (SD¼7.4), po0.01)
(Fig. 3A, C and D). IL-31 stimulation did not reduce the number of
ciliated cells compared with unstimulated (IL-31 stimulation:
mean¼13.6% (SD¼7.0); unstimulated: mean¼15.9% (SD¼7.4))
(Fig. 3A, C and E). We did not ﬁnd that the IL-13/IL-31 combination
stimulation had any additional effect to that of IL-13 alone showing a
similar signiﬁcant difference compared with unstimulated (IL-13/IL-
31 combination stimuation: mean¼5.1% (SD¼4.6); unstimulated:
mean¼15.9%, (SD¼7.4), po0.01) (Fig. 3A, C and F). Stimulation with
IL-13 showed a slight increase in goblet cell number whereas IL-31
Fig. 1. Representative images of unstimulated cultures under maximum intensity (A) and composite z-stack (B); cultures stimulated with 20 ng/ml IL-13 under maximum
intensity (C) and composite z-stack (D); cultures stimulated with 20 ng/ml IL-31 under maximum intensity (E) and composite z-stack (F); cultures stimulated with an
IL-13/IL-31 combination under maximum intensity (G) and composite z-stack (H) stained for the IL-31-RA from WD-PBECs at day 21 culture at ALI and negative control
images under maximum intensity (I) and composite z-stack (J). IL-31-RA presence is indicated by green staining with nuclei indicated by blue staining with DAPI (40).
J.C. Parker et al. / Results in Immunology 2 (2012) 104–111 107
7 14 21
0
250
500
750
1000
Unstimulated
20 ng/ml IL-13
20ng/ml IL-31
20ng/ml IL-13/IL-31
n = 6
Day
TE
E
R
 (o
hm
.c
m
2 )
Fig. 2. TEER of WD-PBECs cultured either unstimulated or stimulated with IL-13,
IL-31 or an IL-13/IL-31 combination for 21 day at ALI. Values are expressed as
mean7SD. No signiﬁcant difference was observed in the TEER values between the
treatment groups.
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IL-13/IL-31 combination stimulation showed similar results to IL-13
alone however there was no statistical signiﬁcance (Fig. 3B and F).
Negative controls showed no evidence of non-speciﬁc binding
(Fig. 3G).
3.4. MUC5AC mRNA and secreted protein remain unchanged by
stimulation with IL-13, IL-31 and an IL-13/IL-31 combination
We found there to be no signiﬁcant difference between
treatment groups and unstimulated cultures however IL-13
stimulation resulted in a 2.84-fold non-signiﬁcant increase of
MUC5AC mRNA (Fig. 4A). Interestingly, the IL-13/IL-31 combina-
tion stimulation did not demonstrate a similar increase when
compared with IL-13 stimulation. We found that all cultures
expressed and secreted MUC5AC mucin onto the apical surface
however we observed no differences between treatment groups
and unstimulated cultures (Fig. 4B).
3.5. Growth factors and chemokines show similar secretion
concentrations regardless of treatment with IL-13, IL-31 and an
IL-13/IL-31 combination
We found that all cultures secreted VEGF, EGF and MCP-1
basolaterally however we observed no signiﬁcant differences
between treatments groups and unstimulated cultures (Fig. 5A–C).4. Discussion
In this study using epithelial cells from healthy children we
conﬁrmed that IL-31-RA is expressed when these cells differenti-
ate. Stimulation of epithelial cells during differentiation with
IL-13 resulted in a slight increase in goblet cells and a signiﬁ-
cantly reduced number of ciliated cells which we have shown
previously using this model [14]. IL-31 appeared to have no
signiﬁcant effect on mucociliary differentiation. Combining IL-13
and IL-31 had no additive effect on altered mucociliary differ-
entiation compared with that observed with IL-13 alone suggest-
ing IL-13 to be the driver of altered differentiation in the
combination stimulation.
Within these relatively non-signiﬁcant results there are inter-
esting points to be noted. Firstly, we detected the presence of the
IL-31-RA on WD-PBECs, conﬁrming previous observations byJawa et al. [37]. Interestingly, however, we found that expression
of IL-31-RA in control cultures, but also in treatment cultures, was
expressed at a level clearly visible using confocal microscopy.
Jawa et al. observed low to undetectable levels in their adult
human primary bronchial cells and in the human bronchial
epithelial immortalised cell line (HBE). These studies were carried
out on monolayer cultures and not on well-differentiated 3-D
cultures which are considered to be a more suitable model for
representing the airway epithelium ex vivo [38]. This may explain
the observational differences between the expression of the
IL-31-RA seen in our cultures compared with the study by Jawa
et al. Secondly, we found that IL-31 had no detrimental effects on
mucociliary differentiation in terms of TEER, goblet and ciliated
cell number, production of MUC5AC mRNA or release of MUC5AC
mucin. To date, relatively little is known as to the role IL-31 plays
in mucociliary differentiation, in particular with respect to airway
remodelling. IL-31 has previously been shown to activate STAT3, a
pathway shared with IL-9 [20]. IL-9 has been implicated in the
pathogenesis of asthma, in particular with altered mucociliary
differentiation [22]. Our study has demonstrated however that
IL-31 played no individual role in altering mucociliary differentia-
tion. Thirdly, we found that IL-31 does not work synergistically
with IL-13 to alter mucociliary differentiation. As with IL-31
alone, we observed no additional signiﬁcant effects on TEER,
goblet and ciliated cell number, MUC5AC mRNA or release of
MUC5AC mucin. Regarding ciliated cells we saw a signiﬁcant
reduction in the number of ciliated cells in IL-13 and IL-13/IL-31
stimulated cultures when compared with unstimulated cultures.
IL-13, in addition to its reported effects on goblet cell hyperplasia
and mucus production, has been shown to reduce ciliated cell
number [14] and this was conﬁrmed in the effects of both
treatments on ciliated cell number. Overall these ﬁndings do
not suggest a major role for IL-31 in the altered differentiation
process of the bronchial epithelium.
Additionally, it has been previously reported by Ip et al. that
IL-31 can signiﬁcantly increase protein expression of VEGF, EGF
and MCP-1 (CCL-2) in BEAS-2B cells and when co-cultured with
eosinophils they observed an augmented response to IL-31
stimulation [26]. We analysed WD-PBECs for VEGF, EGF and
MCP-1 protein secretion following stimulation with all treat-
ments and found that there was no signiﬁcant difference between
unstimulated and any of the treatments including IL-31 alone.
This lack of effect may be explained by the differences in the type
of cell used. BEAS-2B is a human bronchial epithelial cell line
transformed with SV40 virus grown in monolayer culture
whereas we used paediatric WD-PBECs to investigate the effects
of IL-31 which we believe to be a more realistic model of the
bronchial epithelium ex vivo. This lack of direct effect of IL-31 on
human primary cells has also been demonstrated in human
primary keratinocytes [40]. Kasraie et al. note that in order to
elicit an IL-31 mediated response from primary keratinocytes the
cells needed ‘primed’ with either Pam3Cys, a TLR-2 ligand, or the
Th1 cytokine IFN-g to elicit a signiﬁcant response following up-
regulation of the IL-31-RA. This may highlight a major difference
in response between cell lines and primary monolayer and well-
differentiated cell cultures. It would be of interest in future
studies to examine this ‘priming’ effect of the IL-31-RA with
TLR-2 ligands and/or Th1 cytokines in WD-PBECs.
Within this study there were a number of weaknesses. It has
been well reported that IL-13 contributes to goblet cell hyperpla-
sia and increased mucus production in a number of models
including cell line, adult primary cells and animal models
[14,39]. However in our study IL13 showed a slight increase in
goblet cell number but not as strongly as had been previously
shown. This effect may have presented itself had the study
numbers been larger. In addition length of time in culture may
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VEGF. Values are mean7SD. We observed no signiﬁcant difference between
treatments and unstimulated cultures. (B) Measurement of basolateral super-
natants at D21 of ALI culture for EGF. Values are mean7SD. We observed no
signiﬁcant difference between treatments and unstimulated cultures. (C) Mea-
surement of basolateral supernatants at D21 of ALI culture for MCP-1. Values are
mean7SD. We observed no signiﬁcant difference between treatments and
unstimulated cultures.
J.C. Parker et al. / Results in Immunology 2 (2012) 104–111110have also played a factor as many studies vary the length of
exposure to IL-13. We exposed our cultures for 21 day at ALI,
however it has been noted that at 28 day ALI culture, signiﬁcant
goblet cell hyperplasia has been recorded. Although the cultures
are fully differentiated at day 21 ALI, any pathogenic effect of
IL-13 may take longer to exhibit its effects on goblet cells and
indeed mucus secretion.
In conclusion, we accept the null hypothesis that IL-31 alone
or combined with IL-13 did not alter mucociliary differentiation
to that of an asthmatic epithelium with three main points to be
made. Firstly, the IL-31-RA receptor is present in on WD-PBECs
although its expression remained unchanged under stimulation
with IL-31 alone or in combination with IL-13. Secondly, IL-31
does not exhibit any detrimental effects on mucociliary differ-
entiation. Thirdly, it appears that IL-31 does not have a synergistic
J.C. Parker et al. / Results in Immunology 2 (2012) 104–111 111effect when combined in culture with IL-13, in the differentiation
process.
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